Key information

🔎 Fund Overview

Clene Inc. is a clinical-stage biopharmaceutical company. The Company is focused on treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. Its drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. Its other products include CNM-ZnAg and CNM-AgZn17. CNM-ZnAg is a spectrum antiviral, antibacterial agent comprised of zinc and silver ions under development to treat infectious disease and to provide immune support for symptom resolution. CNM-AgZn17 is a gel polymer suspension of zinc and silver under development for treatment of infectious diseases and to support wound healing.